|
Jul 31
|
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
|
|
Jul 31
|
BioArtic: Latest data presented at AAIC 2025 reinforces lecanemab's clinical effect with consistent safety profile
|
|
Jul 22
|
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025
|
|
Jul 16
|
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association
|
|
May 22
|
European Stock Picks That May Be Undervalued In May 2025
|
|
May 15
|
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026)
|
|
Oct 8
|
3 High Growth Swedish Tech Stocks To Watch
|
|
Oct 8
|
Top Swedish Growth Companies With High Insider Ownership In October 2024
|
|
Jul 25
|
Swedish Growth Companies With High Insider Ownership And 31% ROE
|
|
Jul 25
|
Swedish Growth Companies With High Insider Ownership In July 2024
|